HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Study ID
- NCT05821361
- Phase
- PHASE2
- Status
- Unknown
Conditions
- Unrescetable Hepatocellular Carcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Not accepted
Interventions
- HAIC+Cadonilimab+Bevacizumab — DRUGCadonilimab: 10mg/kg, iv,q3w Bevacizumab: 7.5mg/kg, iv, q3w HAIC: Oxaliplatin plus Fluorouracil/Leucovorin
Study Details
To evaluate the efficacy and safety of HAIC combined with Cadonilimab and bevacizumab as first-line therapy in Unresectable hepatocellular carcinoma
Key Dates
- First listed
- Apr 20, 2023
- Start date
- Aug 1, 2023
- Status verified
- Apr 2023
- Primary completion
- Aug 1, 2024
- Completion
- Aug 1, 2025
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: HAIC+cadonilimab+bev
Primary Outcome Measure
Overall response rate ( ORR) per RECIST 1.1 [ Time Frame: Up to 1 year ]